Chemistry: analytical and immunological testing – Peptide – protein or amino acid
Reexamination Certificate
2006-07-24
2009-06-16
Wallenhorst, Maureen M (Department: 1797)
Chemistry: analytical and immunological testing
Peptide, protein or amino acid
C436S501000, C436S518000, C436S536000, C436S811000, C436S815000
Reexamination Certificate
active
07547553
ABSTRACT:
An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample.
REFERENCES:
patent: 2004/090546 (2004-10-01), None
International Preliminary Report on Patentability for PCT/EP2006/007272.
Frank et al., “Biological markers for therapeutic trials in Alzheimer's disease—Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease”, Neurobiology of Aging 24 (2003) 521-536.
Teunissen et al., “Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid”, Neurobiology of Aging 23 (2002) 485-508.
Beinfeld et al., “Prohormone and proneuropeptide processing”, Endocrine vol. 8(1), Feb. 1998, 1-5.
Beltowski et al., “Adrenomedullin—What do we know 10 years since its Discovery?” Polish Journal of Pharmacology, 2004, vol. 56, 5-27.
Bunton et al., “The clinical relevance of adrenomedullin: a promising profile?”, Pharmacology & Therapeutics 103 (2004), 179-201.
Chu et al., “Studies of the microvascular effects of adrenomedullin and related peptides”, Peptides 22 (2001) 1881-1886.
Elsasser et al., “Adrenomedullin Binding Protein in the Plasma of Multiple Species: Characterization by Radioligand Blotting”, Endocrinology, vol. 140(10), 4908-4911.
Tanenao ETO, “A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides”, Peptides 22 (2001), 1693-1711.
David S. Geldmacher, MD., “Dementia with Lewy bodies: Diagnosis and clinical approach”, Cleveland Clinic Journal of Medicine, vol. 71(10), Oct. 2004, 789-800.
Growdon et al., Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer's Disease”, [The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group], Neurobiology of Aging, vol. 19(2), 1998, 109-116.
Ichiki et al., “Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma”, FEBS Letters, 338 (1994), 6-10.
Kis et al., “Adrenomedullin in the cerebral circulation”, Peptides 22, (2001) 1825-1834.
Kitamura et al., Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP), FEBS Letters 351 (1994), 35-37.
Kitamura et al., “Adrenomedullin and PAMP: Discovery, Structures, and Cardiovascular Functions”, Microscopy Research and Technique, vol. 57 (2002), 3-13.
Meeran et al., “Circulating Adrenomedullin Does Not Regulate Systemic Blood Pressure but Increases Plasma Prolactin after Intravenous Infusion in Humans: A Pharmacokinetic Study”, Journal of Clinical Endocrinology and Metabolism, vol. 82(1), 95-100.
Morgenthaler et al., “Measurement of mid regional proadrenomedullin (MR-proADM) in plasma with an immunoluminometric assay”, Clinical Chemistry, 2005, 1-25.
Nicholls et al., “Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man”, Peptides 22 (2001), 1745-1752.
Satoh et al., “Adrenomedullin in Human Brain, Adrenal Glands and Tumor Tissues of Pheochromocytoma, Ganglioneuroblastoma and Neuroblastoma”, Journal of Clinical Endocrinology and Metabolism, vol. 80(5), 1750-1752.
Dennis J. Selkoe, “Alzheimer's Disease: Genes, Proteins, and Therapy”, Physiological Reviews vol. 81: 741-766.
Stroud et al., “Signal sequence recognition and protein targeting”, Current Opinion Structure Biology, 9, 754-9.
Struck et al., “Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients”, Peptides 25 (2004), 1369-1372.
Sugo et al., “Endothelial Cells Actively Synthesize and Secrete Adrenomedullin”, Biochemical and Biophysical Research Communications, vol. 201(3), Jun. 1994, 1160-1166.
Elisabeth Tarkowski, “Cytokines in Dementias”, Current Drug Targets—Inflammation & Allergy, 2002, vol. 1(2), 193-200.
Tarkowski et al., “Cerebral pattern of pro-and anti-inflammatory cytokines in dementias”, Brain Research Bulletin 61 (2003), 255-260.
Taylor et al., “Adrenomedullin and central cardiovascular regulation”, Peptides 22 (2001) 1803-1807.
Teunissen et al., “Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid”, Neurobiology of Aging 23 (2002) 485-508.
I.G. McKeith, “Dementia with lewy bodies”, British Hournal of Psychiatry 180 (2002), 144-147.
Bergmann Andreas
Ernst Andrea
Hampel Harald
B.R.A.H.M.S. Aktiengesellschaft
Heslin Rothenberg Farley & & Mesiti P.C.
Moss Keri A
Wallenhorst Maureen M
LandOfFree
In vitro method for the diagnosis of neurodegenerative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with In vitro method for the diagnosis of neurodegenerative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and In vitro method for the diagnosis of neurodegenerative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4102277